跳至主要内容
临床试验/NCT04574089
NCT04574089招募中3 期

Medical Ethics Committee of Peking University Shenzhen Hospital

Peking University Shenzhen Hospital1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2020年5月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
50
试验地点
1
主要终点
Cure rate

研究概览

简要总结

Aerobic vaginitis was treated by using Baofukang Suppository 7 days group or Baofukang Suppository 14 days group.To evaluate the efficacy and safety after treatment.

详细描述

Aerobic vaginitis was treated by using Baofukang Suppository 7 days group or Baofukang Suppository 14 days group.

Group 1: Baofukang Suppository (1.74g), for vaginal use, 2 capsules per night for 7 days.

Group 2: Baofukang Suppository (1.74g), for vaginal use, 2 capsules per night for 14 days.

The efficacy and safety will be evaluated 7~14 days after treatment and 35~42 days after treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Aerobic vaginitis diagnosed based on present :
  • Vaginal dischareg ;
  • Donders score≥3;

排除标准

  • Patients with other vaginitis, cervical erosion, or suspected gonorrhea, herpes simplex virus infection and other vulvar diseases;
  • Patients received systemic or vaginal antifungal or antibiotic treatment within two weeks before admission.
  • Pregnancy, lactation and intentional pregnancy;
  • Women with liver and kidney dysfunction, low immune function, diabetes, psychosis or other serious diseases;
  • Allergic constitution and patients allergic to drug ingredients in this study;
  • Those with poor compliance.

结局指标

主要结局

Cure rate

时间窗: First month after the treatment

A vaginal smear composite Donders score of 1 to 2 represents normality. A score of more than 2 is aerobic vaginitis. There are four variables(Lactobacillary; leucocytes; toxic leukocytes; parabasal cells; background flora).Detail see folowing references.

次要结局

  • Side affect(First week after treatment)

研究者

发起方
Peking University Shenzhen Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Shangrong Fan

Principal Investigator

Peking University Shenzhen Hospital

研究点 (1)

Loading locations...

相似试验